He added that "the bill ultimately lands on premium payers, taxpayers and, in some cases, on patients who lose coverage or face new hurdles." The authors said additional research is needed to identify policies that could reduce both overall spending and patients' out-of-pocket costs while maintaining access to the medications
Reported positive in December 2025, first Phase 3 readout of the program
The most popular choice
Image reverses show they appear on unrelated skincare or supplement ads
By linking genomic variation, functional traits, and environmental context, we generate data that strengthen pathogen surveillance, support risk-based decision-making, and inform regulatory science
Lincoff, MD, Professor of Neurology